Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;45(3):220-9.
doi: 10.3109/07853890.2012.732234. Epub 2012 Oct 30.

Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans

Zhen Wang  1 , Hong Zhang, Xu-Hui Shen, Kui-Li Jin, Guo-Fen Ye, Wei Qiu, Li Qian, Bo Li, Yong-Hong Zhang, Guo-Ping Shi
Affiliations

Immunoglobulin E and mast cell proteases are potential risk factors of impaired fasting glucose and impaired glucose tolerance in humans

Zhen Wang et al. Ann Med. 2013 May.

Abstract

Aim: Mast cells are important in experimental diabetes. Plasma levels of immunoglobulin E (IgE), tryptases, and chymases are inflammatory markers of human diabetes. Whether they also correlate with the risk of pre-diabetes, however, remains unknown.

Methods and results: A total of 260 subjects 55-75 years of age were grouped as normal glucose tolerance (NGT), isolated impaired fasting glucose (I-IFG), isolated impaired glucose tolerance (I-IGT), and mixed IFG/IGT. There were significant differences in plasma levels of high-sensitivity C-reactive protein (hsCRP) (P < 0.001) and IgE (P = 0.003) among all subgroups of pre-diabetes, and chymase in I-IGT (P = 0.043) and mixed IFG/IGT (P = 0.037) subgroups compared with NGT group. High-sensitivity CRP was a risk factor in all subgroups of pre-diabetes; IgE was a risk factor of mixed IFG/IGT; and chymase was a risk factor of I-IGT and mixed IFG/IGT. Interactions between hsCRP and high waist circumference (WC), waist-to-hip ratio (WHR), or HOMA-β index, and interactions between IgE and high WC or tryptase levels all increased further the risk of developing I-IFG, I-IGT, or mixed IFG/IGT.

Conclusion: Plasma hsCRP, IgE, and chymase levels associate with pre-diabetes status. While hsCRP, IgE, and chymase are individual risk factors of pre-diabetes, interactions with metabolic parameters increased further the risk of pre-diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest: This work was supported by awards from the Huzhou Municipal Science and Technology Agency (2008GS09) (H.Z.), the Zhejiang Province Department of Health (2008B178) (Z.W.), and the Zhejiang Province Department of Education (20070470) (X.H.S.); by grants from the National Institutes of Health HL60942, HL81090, HL88547 (G.P.S.); and by an EIA award (0840118N) from the American Heart Association (G.P.S.). The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Box plots of hsCRP, IgE, chymase, and tryptase among NGT patients and patients with different categories of pre-diabetes. A: Plasma hsCRP levels from NGT, I-IFG, I-IGT, and mixed IFG/IGT patients. B: Plasma IgE levels from the same four categories. C: Plasma IgE levels in male subjects. D: Plasma IgE levels in female subjects. E: Plasma chymase levels. F: Plasma tryptase levels. All data are mean ± SD. P < 0.05 was considered statistically significant; non-parametric Mann–Whitney U test. Non-significant comparisons are not shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;33:S62–9. - PMC - PubMed
    1. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708–23. - PubMed
    1. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285:2109–13. - PubMed
    1. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T, et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care. 2003;26:868–74. - PubMed
    1. Valensi P, Schwarz EH, Hall M, Felton AM, Maldonato A, Mathieu C. Pre-diabetes essential action: a European perspective. Diabetes Metab. 2005;31:606–20. - PubMed

Publication types

MeSH terms